Suzhou, China and Cambridge, Massachusetts, USA, October 18th, 2024 - MediLink Therapeutics (Suzhou) Co., Ltd. ("MediLink"), a clinical-stage biotech company, today announces the appointment of Bruce Chabner, M.D., as Senior Strategic Advisor. Dr. Chabner will serve as a key Scientific Advisory Board member to the MediLink leadership team and bring his significant expertise in medical oncology to help strengthen MediLink’s global development efforts on its next-generation antibody drug conjugate pipelines.
2024-10-18
Suzhou, China, October 8, 2024 - MediLink Therapeutics (Suzhou) Co., Ltd. ("MediLink"), a clinical-stage biotech company, today announced a global clinical trial collaboration and supply agreement with Amgen Inc. Amgen will lead a global clinical study to evaluate the therapeutic potential of the combination of MediLink's B7-H3-targeting antibody-drug conjugate (ADC) YL201 and Amgen's DLL3- and CD3-targeting bispecific T-cell engager (BiTE®) IMDELLTRA™ in extensive-stage small cell lung cancer (ES-SCLC) under the clinical trial collaboration and supply agreement. MediLink will provide the investigational drug YL201 for the combination study.
2024-10-08
Boston, USA, September 26, 2024 -- The annual most valuable biotech selection by Endpoints News, "The Endpoints 11 award", was announced. MediLink therapeutics (“MediLink”) was selected as one, and the only one from China, of the E11 2024 award recipients.
2024-09-27
